Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Bartos

Interventional Cardiology Minneapolis, MN Medical Doctor

NPI 1366755878 CMS profile 1386935

420 Delaware St Se, Mmc276, Minneapolis, MN 55455

Open in the dashboard

General payments

$6,972

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Bartos of Minneapolis, MN is reported in the CMS Open Payments database as having received $6,972 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $604 10
2024 General $567 10
2023 General $792 12
2022 General $2,237 18
2021 General $848 9
2020 General $223 5
2019 General $1,701 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Bartos
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jason Bartos were reported at $604. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jason Bartos Interventional Cardiology median Middle half National median
2019 $1,701 $1,097 $329–$3,048 $163
2020 $223 $473 $161–$1,480 $114
2021 $848 $677 $233–$1,827 $132
2022 $2,237 $978 $333–$2,724 $149
2023 $792 $1,136 $382–$2,986 $160
2024 $567 $1,181 $395–$3,326 $164
2025 $604 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Maquet Cardiovascular U.S. Sales, L.L.C. $2,947 37 payments
  2. Stryker Corporation $637 3 payments
  3. Boston Scientific Corporation $595 5 payments
  4. AngioDynamics, Inc. $490 10 payments
  5. Abbott Laboratories $406 5 payments
  6. Medtronic, Inc. $338 5 payments
  7. Edwards Lifesciences Corporation $329 3 payments
  8. ZOLL Circulation Inc $257 2 payments
  9. Abiomed $251 2 payments
  10. Inari Medical, Inc. $244 2 payments
  11. Other $478 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,699 81 payments
  2. Consulting Fee $1,600 1 payment
  3. Travel and Lodging $673 2 payments
Products named General payments · program years 2019–2025
  1. Cardiohelp Cardiology/Vascular Diseases $2,030 17 payments
  2. LUCAS 3 $633 2 payments
  3. CARDIOHELP Cardiology/Vascular Diseases $478 9 payments
  4. ANGIOVAC $391 6 payments
  5. Impella $251 2 payments
  6. Cardiohelp Cardiology/Vascular Diseases $250 4 payments
  7. 2ND GEN CENTRIMAG PRIMARY CONSOLE $173 1 payment
  8. Resolute $150 1 payment
  9. FlowTriever $149 1 payment
  10. ClotTriever $149 1 payment
  11. Other $2,740 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

262

Median for Interventional Cardiology: 2,236

Drug cost

$18,915

Median for Interventional Cardiology: $380,412

Branded share of claims

21.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 22 $15,510
Atorvastatin Calcium Generic 51 $717
Metoprolol Succinate Generic 36 $627
Carvedilol Generic 24 $570
Clopidogrel Clopidogrel Bisulfate Brand 35 $547
Losartan Potassium Generic 22 $325
Rosuvastatin Calcium Generic 25 $232
Lisinopril Generic 27 $201
Amlodipine Besylate Generic 20 $185

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$69,898

Medicare's payments for the services billed

Medicare patients

140

Average age 68

Services billed

604

49 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 65%
Chronic kidney disease 56%
Diabetes 49%
Atrial fibrillation 42%
Arthritis 41%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record